The pretty worthless CEO (Marc Beer) seems to see worth, suddenly, in $AEGR. He minions seem to follow suit (instead of firing him) so I would expect them to do the same. Also, the corrective active cNBC video is supposed to be out this month. May, certainly, is getting long in the tooth so that could be a bump. The end of the resolve of the FDA warning letter and an end of the DOJ investigation (with possible fines) are other possibilities.
I am a private investor and only gain according to the success of my investments. I receive no other income/salary/financial compensation for my reports and views. Accuracy is positive. Illumination of existing facts is positive. Inaccuracy and obfuscation are negative. My articles and comments are positive. If you read the reports, you will realize that the facts I present were mostly provided by the scientists that work on AEGR's drug, AEGR's SEC filings, other scientists, rival companies, and comments by management. Get the facts from AEGR management and the scientists associated with it.
seems like Aegr is dead money for now, since sales and becoming profitable by Q4 are the only real indicators of the company's success/failures that we have to look forward to. Maybe some phase trial data from Japan? Seems like this is dead money for now and a long term play
How about you tell us how much you are being paid to consistently post negative articles about the company (more than half of which are either out of context or have no merit)? When will you cover your short position?
It's, basically, his life's work for the past couple of years. He's, clearly, been paid for it. Yet he's taken a major break from it too when he couldn't show the ability to move it below $40. I think, finally, his employer realized all the major and minor moves in this stock have been (surprise) due to the company, and not caused by someone with 200 twitter followers (many of whom are just trying to sell him something as well).
We are better positioned than kynamro and they just revised $10 million below previous guidance.
It's a steal from here. Glta.
Somehow i tend to lean towards the analysis of professionals, who are well trained, do this for a living and have rational thoughts as opposed to some of the nonsense and the yahoos on this board.
My name is matt berry. Jetmanbash is someone else. Since you are calling out for identities, why don't you identify yourself. Why are you anonymous?
This is certainly compelling now. Average price target of $82.20, that is an expected return of 161%. I would say that the reward is far greater than the risk, specifically for a company that is due to be cash flow positive within next 2 quarters and has ample cash to fund operations in the meantime. Let alone a drug that will double sales this year and next.
Thanks - I'm hearing other people around and they say otherwise. Insurance, of course, is the trick. Yet a good PR department will handle it.
Hearing other people around, I gather that combo will essentially never be required
Sentiment: Strong Buy
Well, this is an interesting conversation between two individual people? I love how much time you guy spend knocking $AEGR, when it only falls due to its merits. It will rise for the same reasons.
All good and valid points. This is a very high risk investment that has become even riskier with Mr. Beer at the helm. At the beginning of the year they had the risk of a 20 year old drug held together with a cotton candy patent. They now have risks of running out of money before they can really make a profit. They have ONE shot on goal and that is it. I wouldn't count on Germany changing their stance, and I wouldn't count on the companies goal of having no country undersell the price in the US by more than 20%. t